Engineered T cell receptors and methods of use
AssigneeBoard of Regents, The University of Texas System
InventorsCassian Yee, Ke Pan
Life of this patent
Estimating the term…
Abstract
This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize cancer testis (CT) antigens of the MAGE-A4 antigen. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.
Claims19
An engineered T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 23-25, respectively, and the TCR-b polypeptide comprises a CDR1, CDR2, and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 14, 15, and 30, respectively.
Dependencies are inferred from the claim text.